Answers are grounded in this paper and cite their sources.
BACKGROUND: Adaptive servoventilation (ASV) is a recently developed ventilation mode designed to stabilize ventilation in patients with central sleep apnea and Cheyne-Stokes respiration. Alternatively, modes aiming to maintain average ventilation over several breaths, such as average volume-assured pressure support (AVAPS) and intelligent volume-assured pressure support (iVAPS), could be efficient during ventilation instability by reducing central events. These modes are available on a variety of devices. This bench evaluation studied the response of these different modes and devices to simulated transient hypoventilation events. METHODS: Three home ventilation devices operating in ASV modes (AirCurve 10 CS Pacewave, ResMed; DreamStation autoSV, Philips; Prisma CR, Löwenstein) and 2 ventilators with the AVAPS mode (DreamStation BiPAP, Philips; Lumis 150 iVAPS, ResMed) were evaluated during transient central hypopnea/hypoventilation simulations characterized by a constant breathing frequency of 15 breaths/min and a progressive decrease of tidal volume (V T ) from 500 mL to 50 mL, in 18, 12, 9, and 6 breaths, respectively, followed by a progressive return to the baseline at the same rate. RESULTS: The AirCurve 10 CS Pacewave reacted to a V T decrease between 80% and 50% of baseline V T . DreamStation BiPAP and Prisma CR reacted when V T decreased to between 60% and 30% of baseline V T , whereas the AVAPS response to hypopnea occurred during the crescendo phase of hypopnea/hypoventilation V T . The iVAPS response was between that of the AirCurve 10 CS Pacewave and the other ASV devices. Among the ASV devices, the minimum V T was higher with AirCurve 10 CS Pacewave, followed by the Prisma CR and the DreamStation BiPAP. Minimum V T was not influenced by AVAPS and was improved by iVAPS without outperforming the AirCurve 10 CS Pacewave. Maximum V T was increased by iVAPS, whereas ASV devices did not induce a significant V T overshoot. CONCLUSIONS: ASV devices improved central hypopnea/hypoventilation events without inducing hyperpnea events and therefore were better adapted than AVAPS and iVAPS devices, with notable differences in their responses to hypoventilation events.
No takes yet. Share an insight, caveat, or question.
Lofaso et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: